Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

KORU Medical Systems, Inc. KRMD

Healthcare — Medical Instruments & Supplies
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.22
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — 4 1 — — 1
Sell — — — — — — — — — — — —
Insider Ownership
6.52%

Capital & Financial Ratios

Market Cap
148.67
Revenue
45.11
Net Income
(1.82)
Free Cash Flow
0.25
Net Debt
(8.22)
Current Ratio
2.72
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
3.30
P/B ratio
8.25
Past 5Y EPS Growth
—
This Y EPS Growth
34.88%
Next Y EPS Growth
152.85%
Next 5Y EPS Growth
41.57%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 11.48 9.58 8.87 8.29
Receivables 4.07 6.00 6.53 6.09
Inventory 3.48 2.80 3.68 4.51
Other — — — —
20.26 19.13 19.99 19.51
2023 2024 2025 Q'26
Payables 0.98 1.65 2.27 2.91
ST’ Debt — — — —
Other 0.51 0.03 0.03 0.01
4.45 7.20 8.19 7.18
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 11.76 12.05 — —
—
’25 9.64 10.19 10.40 10.90
41.13
’24 8.20 8.43 8.18 8.84
33.65
’23 7.39 6.94 7.00 7.19
28.52
’22 6.24 6.55 7.76 7.34
27.90
’21 5.43 5.53 6.04 6.49
23.49
’20 6.33 7.71 6.08 4.06
24.18
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 0.01 0.22 — —
—
’25 (0.24) (0.46) 0.07 1.09
0.46
’24 (0.35) 0.01 (0.92) 0.94
(0.32)
’23 (4.66) (0.15) (1.17) 1.10
(4.89)
’22 (1.75) (2.87) (2.12) 1.34
(5.40)
’21 (2.61) (0.17) (0.83) (0.72)
(4.32)
’20 0.15 2.55 (1.74) (1.71)
(0.74)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (0.08) (0.36) — —
—
’25 (0.68) (0.49) 0.01 0.67
(0.49)
’24 (0.48) (0.14) (2.03) 0.99
(1.65)
’23 (4.94) (0.26) (1.39) 0.89
(5.71)
’22 (2.50) (4.05) (2.76) 1.11
(8.21)
’21 (2.71) (0.24) (0.98) (0.76)
(4.69)
’20 (0.03) 2.22 (2.23) (1.74)
(1.78)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.02) 0.01 — —
—
’25 (0.03) 0.00 (0.02) (0.01)
(0.06)
’24 (0.04) (0.02) (0.03) (0.03)
(0.13)
’23 (0.05) (0.05) (0.03) (0.16)
(0.30)
’22 (0.06) (0.07) (0.03) (0.04)
(0.19)
’21 (0.03) (0.03) (0.02) (0.02)
(0.10)
’20 0.01 (0.03) 0.01 (0.02)
(0.03)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ 1.82 2.00 1.98 1.86 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 3.68 4.48 4.60 6.61 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 86 82 80 73 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.32 0.35 0.42 0.56 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.90 28.52 33.65 41.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55.09% 58.59% 63.40% 62.26% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (10.68) (9.77) (6.06) (2.62) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.27%) (34.27%) (18.02%) (6.36%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.66) (13.74) (6.07) (2.64) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.59 0.87 0.89 0.81 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.62 0.63 0.73 0.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (0.19) (0.30) (0.13) (0.06) ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.12) (0.11) (0.01) 0.01 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.06) (0.02) (0.03) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.18) (0.13) (0.04) (0.01) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.70 0.45 0.37 0.37 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 45.00 45.60 45.80 46.19 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.73 3.81 5.24 6.52 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.10 5.33 10.49 15.74 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.15 3.45 4.99 6.33 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.50) (17.22) (101.58) (534.42) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.40) (4.89) (0.32) 0.46 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.80) (0.81) (1.33) (0.95) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.21) (5.71) (1.65) (0.49) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.84 15.80 11.93 11.79 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.27 0.32 0.20 0.08 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.14) (11.17) (9.38) (8.79) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.33 20.35 16.81 17.05 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.71%) (38.82%) (21.79%) (9.52%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.36%) (69.86%) (54.19%) (22.51%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (25.54%) (53.18%) (32.64%) (15.58%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

KORU Medical Systems (KRMD) dazzles with revenue nearly tripling since 2016 to $33.6 million in 2024, accelerating to 18% growth lately, fueled by efficient scaling of its Freedom Infusion System and productivity surges like 89% higher revenue per employee. Analysts forecast 17-22% CAGR through 2027, painting a path to tepid profitability. Yet, this niche medtech player’s glossy top-line hides a profitability black hole: cumulative losses over $40 million in five years, cash burn persisting into 2024, and metrics like -54% ROIC screaming inefficiency amid dilution and volatile gross margins.

The balance sheet offers a net cash cushion, but equity erosion, insider silence (zero trades in over a year), and rich valuations—5.2x PS for a perennial lossmaker—signal a disconnect from frothy analyst targets implying up to 71% upside. Stock highs near 2024 peaks echo 2020 hype, but history warns of 85% wipeouts when reality bites, from reimbursement risks to competition.

Contrarians see a high-stakes gamble: growth tempts, but execution chokepoints like FCF inflection loom large. Will KRMD finally deliver, or fade into medtech mediocrity? Dive into the full analysis for the unvarnished risks.

Read full commentary →

KORU Medical Systems, Inc. (KRMD) Latest News

News by impact score

Fine-tune

12 Aug

3 transcript www.fool.com, 7:01 PM
KORU Medical Systems, Inc. (KRMD) released the transcript of its Q2 2026 earnings call covering financial results, operations, and outlook. Earnings call transcripts detail quarterly results and guidance that can moderately shift investor sentiment and near-term stock performance.

6 Aug

4 transcript , 1:07 AM
KORU Medical Systems Inc reported record revenue and first milestone achievement in its Q2 2026 earnings call. Record revenue signals strong growth that can materially lift financial outlook and investor sentiment.

5 Aug

3 www.marketbeat.com, 10:04 PM
KORU Medical Systems held its Q2 earnings call and reported financial results along with operational highlights. Quarterly earnings updates supply performance data that may shift short-term sentiment without major strategic change.

3 transcript app.moby.co, 9:57 PM
KORU Medical Systems, Inc. summarized its Q2 2026 earnings call covering financial results and operational updates. Earnings call reveals key financial metrics affecting investor views on company performance.

3 , 6:10 PM
KORU Medical Systems, Inc. beat Q2 earnings and revenue estimates. Q2 earnings and revenue beats can lift short-term stock performance and sentiment.

3 , 4:05 PM
KORU Medical Systems reported second quarter 2026 results and updated full year 2026 guidance. Quarterly results and guidance revisions directly shape near-term financial outlook and investor views.

7 May

3 app.moby.co, 8:30 AM
KORU Medical Systems, Inc. (KRMD) released Q1 2026 earnings call summary detailing quarterly financial performance, operational updates, and future outlook. Quarterly earnings disclosures moderately influence KRMD's financial metrics and investor sentiment.

6 May

4 www.marketbeat.com, 10:16 PM
KORU Medical Systems (KRMD) released Q1 earnings call highlights detailing financial results, revenue growth, operational updates, and forward guidance. Q1 earnings call highlights disclose key financial metrics, strategic initiatives, and outlook that could significantly sway KRMD's market performance and investor confidence.

4 Business Wire, 4:05 PM
KORU Medical Systems, Inc. (KRMD) announced First Quarter 2026 financial results. Quarterly earnings announcements drive significant shifts in financial performance, stock valuation, and investor sentiment for KRMD.

1 May

3 Simply Wall St., 7:51 AM
KORU Medical Systems (NASDAQ:KRMD) holds strong financial position with ample cash reserves and low debt, enabling aggressive business growth investments without straining resources. KRMD's robust balance sheet supports growth initiatives, potentially boosting financial performance and investor sentiment moderately.

17 Mar

4 Zacks, 11:36 AM
KORU Medical Systems, Inc. (KRMD) secured EU MDR certification for its Freedom60 Infusion Pump, enabling sales across the European Union and supporting expansion in subcutaneous infusion therapy markets. EU MDR certification unlocks European market access for the Freedom60 Infusion Pump, driving potential revenue growth and enhancing competitive positioning.

13 Mar

4 app.moby.co, 8:30 AM
KORU Medical Systems, Inc. released Q4 2025 earnings call summary detailing financial results, operational highlights, strategic updates, and forward guidance. Q4 earnings call summary discloses critical financial metrics, growth strategies, and outlook likely to drive substantial shifts in investor sentiment and stock performance.

4 Business Wire, 8:00 AM
KORU Medical Systems, Inc. (KRMD) announces EU MDR certification for its Freedom60® Infusion Pump, enabling compatibility with prefilled syringes and facilitating commercialization across the European Union. EU MDR certification unlocks European market access for KRMD's flagship infusion pump with enhanced prefilled syringe compatibility, driving revenue growth and competitive positioning.

12 Mar

4 GuruFocus.com, 11:06 PM
KORU Medical Systems Inc. (KRMD) Q4 2025 earnings call highlights strong revenue growth alongside other key financial and operational advancements. Strong revenue growth in Q4 2025 earnings call indicates significant positive momentum for KRMD's financial performance and investor sentiment.

4 www.marketbeat.com, 8:46 PM
KORU Medical Systems (KRMD) released Q4 earnings call highlights, covering financial results, operational achievements, growth initiatives, and forward guidance. Q4 earnings call highlights detail financial performance and strategic outlook, poised to significantly sway KRMD's investor sentiment and trajectory.

4 Business Wire, 4:08 PM
KORU Medical Systems, Inc. (KRMD) announces CEO transition with current CEO Linda Tharby stepping down and Cormac Shepherd appointed as interim CEO effective immediately. CEO transition signals major leadership change that could reshape strategic direction and impact investor sentiment and market performance.

4 Business Wire, 4:05 PM
KORU Medical Systems reports +20% revenue growth for Q4 and full-year 2025, positive adjusted EBITDA, and initiates full-year 2026 guidance. 20%+ revenue growth, positive adjusted EBITDA, and 2026 guidance demonstrate strong financial momentum and enhanced market positioning.

3 Zacks, 5:35 PM
KORU Medical Systems, Inc. (KRMD) reported a Q4 loss but beat revenue estimates. Q4 revenue beat despite loss moderately influences financial performance and investor sentiment without fundamentally altering trajectory.

12 Feb

3 Zacks, 9:35 AM
KORU Medical Systems, Inc. (KRMD) has seen an 18.1% decline in stock value over the past four weeks, attributed to broader market trends and specific company challenges. Analysts suggest that the stock may be undervalued, indicating potential for a turnaround as the company continues to innovate in the medical device sector. Investors are advised to monitor upcoming developments closely, as positive changes could lead to a rebound in stock performance. The company's recent stock decline and potential for innovation suggest a moderately noticeable influence on its future performance.

10 Feb

3 Simply Wall St., 12:38 PM
KORU Medical Systems, Inc. (KRMD) is highlighted in February 2026 for being estimated below its intrinsic value, suggesting potential for growth. Analysts indicate that the company's current stock price does not reflect its underlying financial health and future prospects. This situation presents an opportunity for investors looking for undervalued stocks in the market. The company's estimated undervaluation may influence investor sentiment and financial performance, but the overall effect is expected to be limited.

3 Simply Wall St., 6:38 AM
KORU Medical Systems, Inc. (KRMD) is identified as one of three stocks potentially undervalued by up to 49.8% compared to their intrinsic value. The analysis highlights the company's growth prospects and market position, suggesting that current stock prices do not reflect its true worth. Investors may find this an opportune moment to consider KRMD for their portfolios, given the significant discrepancy between market valuation and intrinsic value. The identification of KRMD as undervalued suggests a moderately noticeable influence on its market performance.

9 Feb

4 Simply Wall St., 6:08 AM
KORU Medical Systems, Inc. (KRMD) is assessed to be 48% undervalued based on intrinsic calculations, indicating a significant discrepancy between its market price and intrinsic value. This valuation suggests potential for growth and investment opportunities as the company continues to develop its product offerings and market presence. The intrinsic valuation indicates a significant opportunity for growth, which could alter investor sentiment and the company's market trajectory.

6 Feb

3 Simply Wall St., 12:38 PM
BillionToOne has identified KORU Medical Systems, Inc. (KRMD) as a potential value stock, suggesting it may offer investment opportunities. The analysis highlights the company's growth prospects and market positioning, indicating that it could be undervalued in the current market environment. KORU Medical Systems is noted for its growth potential, which may moderately influence its market performance.

3 Simply Wall St., 6:38 AM
KORU Medical Systems, Inc. (KRMD) is highlighted as potentially undervalued in February 2026, alongside two other stocks. Analysts suggest that KRMD's innovative product offerings and market positioning may not be fully reflected in its current stock price, indicating a possible opportunity for investors. The company's focus on enhancing patient care through its medical devices is noted as a key factor in its growth potential. KORU Medical's innovative products and market positioning may moderately influence its financial performance and competitive standing.

3 Feb

3 , 7:13 AM
KORU Medical Systems, Inc. (KRMD) experienced a notable increase of 5.6% in its stock price, raising questions about the potential for further gains. Analysts are evaluating the factors contributing to this rise and whether the momentum can be sustained in the coming weeks. Market sentiment appears positive, but investors are advised to consider various elements that could influence future performance. The stock's recent increase suggests a moderately noticeable influence on market sentiment and potential financial performance.

30 Jan

4 www.medicaldevice-network.com, 7:01 AM
KORU Medical Systems, Inc. has received FDA clearance for its FreedomEDGE infusion system, a significant advancement in their product offerings. This system is designed to enhance patient care by providing a more efficient and user-friendly infusion experience. The FDA clearance is expected to facilitate the system's entry into the market, potentially improving KORU's competitive position and financial performance. FDA clearance for a new infusion system is a significant regulatory milestone that can enhance market positioning and revenue potential.

29 Jan

4 Business Wire, 4:05 PM
KORU Medical Systems, Inc. has received FDA 510(k) clearance for the delivery of RYSTIGGO® (rozanolixizumab-noli), which expands the label for its FreedomEDGE® Infusion System. This clearance allows for the use of the infusion system in delivering the new treatment, enhancing the company's product offerings in the market. The FDA clearance represents a significant regulatory milestone that could enhance product adoption and market positioning.

21 Jan

4 Zacks, 12:00 PM
KORU Medical Systems, Inc. (KRMD) has received a rating upgrade to 'Buy' from analysts, reflecting positive sentiment about the company's growth potential and market position. The upgrade is based on recent developments in product offerings and anticipated financial performance improvements. Investors are encouraged to consider this upgrade as a signal of confidence in KRMD's future prospects. The rating upgrade indicates significant positive sentiment and potential for improved market performance.

12 Jan

4 Business Wire, 8:00 AM
KORU Medical Systems, Inc. (KRMD) reported preliminary results for Q4 and the full year 2025, achieving record revenue and positive operating cash flow for the year. The company highlighted significant growth in its financial performance, indicating a strong operational trajectory. Record revenue and positive cash flow suggest a significant improvement in the company's financial health and market position.

9 Jan

4 ZacksZacksZacksZacksMotley FoolZacksZacksBarchart, 9:18 AM
KORU Medical Systems, Inc. (KRMD) is highlighted among three MedTech stocks that have significantly outperformed the S&P 500 over the past year. The company has shown strong growth and innovation in its product offerings, contributing to its competitive edge in the market. Investors are encouraged to consider KRMD as a promising option due to its robust performance metrics and strategic positioning within the MedTech sector. KORU Medical's strong growth and innovation are likely to significantly impact its future performance and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us